ESMO20: olaparib recommended for combination with bevacizumab in ovarian cancer

Written by Rachel Jenkins, Future Science Group

olaparib bevacizumab combination

Olaparib, also known as Lynparza, has been recommended for marketing authorization in the EU in combination with bevacizumab for the first-line maintenance treatment of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer. The recommendation, from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, was based on the recently published PAOLA-1 Phase III trial (NCT02477644). José Baselga, Executive Vice President at AstraZeneca (MD, USA) – the company responsible for olaparib – commented: “Half of all newly diagnosed patients with advanced ovarian cancer have HRD-positive tumors. Lynparza together with bevacizumab has demonstrated a median PFS...

To view this content, please register now for access

It's completely free